Morgan Stanley Downgrades Globus Medical (GMED) to Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St futures subdued as Nvidia results, inflation take center stage
- Oil drops to more than two-week low on Iran-Oman talks to reopen Strait of Hormuz
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
UPDATE: Canaccord Genuity Downgrades Globus Medical (GMED) to Hold
July 27, 2016 7:17 AM EDT(Updated - July 27, 2016 10:39 AM EDT)
Canaccord Genuity downgraded Globus Medical (NYSE: GMED) from Buy to Hold with a price target of $28.00 (from $30.00). Analyst Kyle Rose expressed concerns that its US business slow to regain momentum.
Rose explained, "We... More
Wells Fargo Upgrades Globus Medical (GMED) to Market Perform
July 27, 2016 7:16 AM EDTWells Fargo upgraded Globus Medical (NYSE: GMED) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Globus Medical click here. For more ratings news on Globus Medical click here.
Shares of Globus Medical closed at $26.43 yesterday.
... MoreLeerink Partners Downgrades Globus Medical (GMED) to Market Perform
July 27, 2016 7:12 AM EDTLeerink Partners downgraded Globus Medical (NYSE: GMED) from Outperform to Market Perform with a price target of $27.00 (from $29.00).
Analyst Richard Newitter commented, "We appreciate that GMED's above avg. EBITDA margin profile has held up despite decelerating 1H16 rev. growth, and acknowledge a better 2017 set-up as comps get easier and key investment initiatives like... More
Globus Medical (GMED) Reports In-Line Q2 EPS
July 26, 2016 4:41 PM EDTGlobus Medical (NYSE: GMED) reported Q2 EPS of $0.29, in-line with the analyst estimate of $0.29. Revenue for the quarter came in at $137.5 million versus the consensus estimate of $141.78 million.
GUIDANCE:
Globus Medical sees FY2016 EPS of $1.20, versus the consensus of $1.20. Globus... More
Globus Medical (GMED) to Acquire Alphatec International Business in $80M Deal
July 26, 2016 4:39 PM EDTGlobus Medical, Inc. (NYSE: GMED) announced that it has entered into an agreement to acquire the international operations and distribution channels of Alphatec Holdings, Inc., a publicly traded medical devices company (Nasdaq: ATEC) for $80.0 million in cash, subject to certain closing adjustments. Globus Medical also agreed to extend a 5-year senior secured credit facility of up to $30.0 million to Alphatec to support their working capital needs. The parties expect the closing of the acquisition to occur by October 2016 following... More
